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Abstract
Background: Both animal and clinical studies have implicated serotonergic dysfunction in the
pathogenesis of alcohol abuse and dependence. However the exact mechanisms involved remain
unknown. Theoretically, low serotonin promotes alcohol seeking behavior. Sumatriptan is a
serotonin1D agonist. It is postulated that sumatriptan's agonism at this terminal autoreceptor
increases negative feedback, creating a net effect of decreased serotonergic neurotransmission.
Administration of sumatriptan should therefore produce a craving for alcohol and the desire to
drink.
Methods: Fifteen patients with alcohol dependence who had undergone detoxification were
recruited. Sumatriptan (100 mg) and placebo was administered in cross-over fashion on 2 separate
days 72 hours apart. Both patients and raters were blind to all treatments.
Patients were assessed on the following scales at -30, 0, 30, 90, 150 and 210 minutes: A 6-item scale
designed to rate the patient's intention to drink; The Sensation Scale; a 13-item affect analog scale
designed to rate the pattern and extent of emotional changes; and an 8-item scale designed to rate
the patient's craving for alcohol
Results: No significant differences were found between the placebo and sumatriptan groups and
no significant cross over effects were found.
Conclusion: The general lack of efficacy of sumatriptan in producing alcohol-like symptoms or a
desire to drink alcohol may suggest that the 5HT1D receptor plays little role in the
pathophysiology of alcoholism.
Background
Both animal and clinical studies have implicated seroton-
ergic dysfunction in the pathogenesis of alcohol abuse
and dependence [1,2]. However the exact mechanisms
involved remain unknown. Pharmacological challenge
studies provide one way of identifying the specific recep-
tor systems involved.
Serotonergic dysfunction is thought particularly to be
involved in alcohol craving. Verheul et al [3] proposed
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three types of craving – reward craving, relief craving and
obsessive craving. Obsessive craving is defined as the loss
of control over intrusive thoughts about alcohol and is
believed to be mediated by a deficit of serotonin.
m-chlorophenylpiperazine (m-CPP) is a serotonin ago-
nist with actions at 5-HT1a, 5-HT1d, 5-HT2c receptors.
The 5HT1a and 5HT1d receptors are autoreceptors and
agonism here has been demonstrated to decrease net ser-
otonergic transmission.[4] m-CPP has been reported to
elicit craving for alcohol and feelings similar to intoxica-
tion in abstinent alcoholics [5,6]). This relates well to ani-
mal studies, where TFMPP administration (a compound
structurally similar to mCPP) has discriminant stimulus
properties similar to low doses of alcohol [7].
Taken together, this suggests that alcohol may be used to
self-medicate in patients with dysequilibrium of the sero-
tonergic system. This hypothesis is given further support
by studies showing the efficacy of serotonergic agents in
the treatment of alcoholism [8-11]. The serotonin system
is, however, complex, and mCPP is a relatively nonselec-
tive agent. In order to delineate further the exact mecha-
nisms involved in alcoholism more selective agents must
be used.
Sumatriptan is a selective serotonin(5HT)1D agonist. It is
postulated that sumatriptan's agonism at this terminal
autoreceptor increases negative feedback, creating a net
effect of decreased serotonergic neurotransmission [4] In
line with Verheul's model of craving [3] sumatriptan
administration, by decreasing serotonergic transmission,
should theoretically produce a desire to drink.
Studies of sumatriptan administration in alcohol depend-
ent patients suggest involvement of the 5HT1D receptor.
Sumatriptan stimulates the release of growth hormone
(GH) and inhibits the release of prolactin in normal indi-
viduals. In both long term and newly abstinent alcoholics
sumatriptan administration did not increase GH secre-
tion, suggesting alteration at the 5HT1D receptor. [12,13]
The 5HT1D receptor may also be associated with repeti-
tive behaviours. In autism, increased GH response to
sumatriptan was noted [14], with the severity of repetitive
behaviours correlating with response. Addictive behav-
iours may be viewed as a type of repetitive behaviour.
Furthermore, in OCD, sumatriptan has been suggested to
produce similar effects to those of mCPP, and its admin-
istration led to exacerbation of symptoms [15], i.e loss of
control over obsessive thoughts. We hypothesized that
effects of sumatriptan would be similar to those of mCPP
in patients with alcoholism, namely that administration
of sumatriptan would potentiate obsessive craving for
alcohol. Should this hypothesis be bourne out, it would
point to specific involvement of the 5HT1d receptor in the
pathophysiology of alcohol craving.
Methods
Fifteen patients with alcohol dependence who had under-
gone detoxification (4 females and 11 males) were
recruited from the acute detoxification units at Tygerberg
and Stikland hospitals, Cape Town, South Africa. All sub-
jects were medically stable, with no history of cardiac dis-
order, and with liver enzymes less than 1.5 times the
maximum laboratory range at baseline. All subjects had at
least seven alcohol and benzodiazepine-free days. For 72
hours prior to the challenge, subjects adhered to a
tyramine-free diet.
Informed written consent was obtained from all subjects
and the ethics committee of the University of Stellenbosch
approved the study. The research was carried out in
accordance with the Declaration of Helsinki of the World
Medical Association. During the study subjects were inpa-
tients at the Alcohol Rehabilitation Unit at Stikland Hos-
pital, and received ongoing psychotherapy. On
completion of a 6 week program, subjects were discharged
to a weekly outpatient therapy group. These measures
were felt to be sufficiently containing to prevent experi-
mentally induced relapse.
Sumatriptan (100 mg) and placebo was administered
orally in cross-over fashion on 2 separate days 72 hours
apart. Sumatriptan was chosen as the challenge agent as it
has the least side effects of the triptans. A drawback
though, is that it has poor penetration of the blood brain
barrier. However, previous work [12,13] has showed
altered hormonal responses in alcohol dependent
patients, suggesting that sufficient amounts do cross over.
Furthermore, in studies of OCD and related disorders,
sumatriptan is the most commonly used challenge agent.
The 100 mg dose was chosen as in previous work on OCD
and OCD related disorders, 100 mg had been shown to
increase obsessions and repetitive behaviours [14,15]
Both patients and raters were blind to all treatments.
Patients were assessed on the following scales at -30, 0 30,
90, 150 and 210 minutes:
1. A 6-item scale designed to rate the patient's intention to
drink. (modified from [6]) Items were rated from 0 (not
at all) to 4 (extremely), and included questions such as "I
would like to drink alcohol" and "I intend to drink alco-
hol in the near future". A 6th question, "the tablet I took
this morning feels similar to alcohol" was also posed.BMC Psychiatry 2005, 5:31 http://www.biomedcentral.com/1471-244X/5/31
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2. The Sensation Scale [16]. Items included side effects
commonly produced by alcohol, such as nausea, facial
flushing, dizziness and numbness. Items were rated from
0 (not at all) to 10 (a great deal).
3. A 13-item affect analog scale designed to rate the pat-
tern and extent of emotional changes[17].
4. An 8-item scale designed to rate the patient's craving for
alcohol. Items included " I crave a drink right now" and "I
want a drink so bad I can taste it". [18]
Statistical analyses were carried on out the total score for
each questionnaireas well specific variables of interest. For
every variable the six sequential observed scores, y1...y6, of
every subject on every occasion were summarized in two
informative statistics, the sum S = y1+y2+y3+y4+y5+y6, and
the linear trend contrast L = -8y1-5y2-2y3+y4+4y5+10y6.
Note that the weights in the L contrast are obtained from
the first order orthogonal polynomial for the unequally
spaced time intervals of observation.
Thus, for a particular variable every subject has two values
of S one for sumatriptan and one for placebo,, say S1 and
S2., and the drug effect is measured by S1-S2. The cross-
over effect is measured by an estimate of the difference in
location of the distribution of S1-S2 in the two groups; it
can be mean(S1-S2, Group 1)-mean((S1-S2, Group2), or
an estimate based on the Wilcoxon Rank Sum test; there
are other possibilities, not used here. In the case of the
mean the natural test statistic is of the form z = (difference
of means)/(s.e. of the difference); note that the Welch ver-
sion of the denominator was used in the calculation of z.
The distribution of this statistic is "t" if the variable S1-S2
is normally distributed, with appropriate adjustment of
the number of degrees of freedom for the Welch version
of the ttest. In the present instance it is not, but being a dif-
ference of linear functions the distribution is symmetric,
and significance levels given by the t-distribution are
robust. However, in marginal cases exact significance lev-
els for z was obtained from a permutation distribution.
Further, in marginal cases the Wilcoxon Rank Sum test
was used for confirmation, or otherwise, of the result.
The linear effect scores, L, were analysed in the same way
as the S scores.
Results
All but 2 measures showed no significant changes (See
table 1). On the variable "anxious" (item 8 of the affect
analog scale) a significant cross over effect was found (z =
-2.36, p = 0.046, df = 8; exact permutation P = 0.031; Wil-
coxon Rank Sum test P = 0.023). In the group that
received sumatriptan first the mean S1-S2 was negative, in
the group that received placebo first it was positive. Nei-
ther mean differs clearly significantly from zero. In the
placebo first group the signficance level attained was 0.08.
(See table 2)
On the intention to drink scale no significant mean effect
was found. In the linear trend scores there is some evi-
dence of a significant crossover effect (t = 2.12, p = 0.058,
df = 11; exact permutation P = 0.075; Wilcoxon Rank Sum
test P = 0.059). Further analysis showed that no signifi-
cant difference in linear trend was found for the group
that received sumatriptan first, but in the group that
received placebo first, a marginally significant linear trend
Table 1: 
Group N Mean SE Mean T p
Affect analog Scale Cross-over effect Placebo first 9 0.0 1.3 -.1.25 0.241
Sumatriptan first 6 2.5 1.5
Linear Trend effect Placebo first 9 -3.7 1.3 -0.91 0.391
Sumatriptan first 6 -4.5 1.5
Intent to drink scale Cross Over effect Placebo first 9 -2.3 4.5 -0.63 0.54
Sumatriptan first 6 0.67 1.7
Linear Trend effect Placebo first 9 16.1 7.9 2.12 0.058
Sumatriptan first 6 -2.67 4.0
Sensation Scale Cross Over effect Placebo first 9 -6.6 24 -0.66 0.52
Sumatriptan first 6 11 11
Linear Trend effect Placebo first 9 -6.8 21 0.80 0.44
Sumatriptan first 6 -27.7 15
Craving Scale Cross Over effect Placebo first 9 -7.4 4.2 -1.92 0.084
Sumatriptan first 6 2 2.4
Linear Trend effect Placebo first 9 3.6 5.9 -0.37 0.72
Sumatriptan first 6 6.3 4.2BMC Psychiatry 2005, 5:31 http://www.biomedcentral.com/1471-244X/5/31
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effect was noted (t = 2.039, two-sided p = 0.07, one-sided
p = 0.04) (See table 3)
Discussion
Our results show that overall sumatriptan has no signifi-
cant ability to provoke alcohol lsymptoms or to cause a
desire or craving for alcohol. The significant placebo effect
on the variable "anxious" may merely represent normal
anxiety when confronted with an unfamiliar task. This is
made especially plausible by the fact that it only occurs in
the group that took placebo first, suggesting that as
patients become more familiar with the trial the anxiety
disappears.
The interpretation of the linear trend on the intention to
drink scale in patients who received placebo first is more
difficult. On its own this suggests that sumatriptan did
cause changes not seen with placebo. However, if this was
true, one would also expect to find a significant linear
trend in the group who received sumatriptan first.
Furthermore, a significant overall drug effect should have
been found. It is more plausible that the trend found is
due either to error introduced by the small group size and
multiple tests, or by factors unrelated to sumatriptan
within the group.
The general lack of efficacy of sumatriptan in producing
alcohol-like symptoms or a desire to drink alcohol may
suggest that the 5HT1D receptor plays little role in the
pathophysiology of alcoholism. This is in contrast to stud-
ies that show decreased GH response to sumatriptan
administration in abstinent alcoholics.
However, several limiting factors must be borne in mind.
Firstly, the sample size was small and consisted of recently
detoxified alcoholics. Chronic use of alcohol may alter the
neurochemical milieu and provide a false picture of recep-
tor involvement in alcoholism [1].
Secondly, sumatriptan has poor penetration of the blood-
brain barrier, and its failure to provoke a response may be
a result of this, rather than lack of involvement of the
5HT1D receptor in the pathogenesis of alcoholism. How-
ever, given that previous work has shown hormonal (in
alcohol dependence) [12,13]and behavioural (in OCD)
responses [15], this is less likely.
Furthermore, it may be that GH response to sumatriptan
does not necessarily correlate with behavioural changes.
In OCD, there have been conflicting reports about symp-
tom exacerbation following sumatriptan challenges, yet a
decreased GH response is observed. It is possible that GH
release is mediated via different pathways to behavioural
effects. This is suggested by the finding in autism, where
increased GH release correlated with severity of repetitive
behaviours. As both OCD and alcohol dependence can be
conceptualized as repetitive behaviours, this contrasts
with findings in these disorders.
Finally, the majority of the sample (11 patients) had late
onset alcohol dependence (age of onset > 25) using the
von Knorring criteria [19]. George et al [20] found ethanol
-like responses to mCPP were only found in the early
onset group. It is possible that we did not observe a
response in our sample as most had late onset alcohol
dependence.
Conclusion
While our study suggests that the 5HT1D receptor does
not play a significant role in the pathogenesis of alcohol-
ism, further studies with sumatriptan and with agents that
have better blood-brain barrier penetration are needed in
Table 2: Cross Over Effect – variable "Anxious" on Affect Analog Scale
Group N Mean SE Mean T p
"Anxious" Cross-over effect Placebo first 9 -0.67 0.33 -2.36 0.046
Sumatriptan first 6 0.83 0.54
Table 3: Linear Trend – Intent to Drink Scale
Group N Mean SE Mean T P
Intent to drink Linear Trend effect Placebo first 9 16.1 7.9 2.039 0.04
Sumatriptan first 6 -2.67 4.0 -.066 0.53Publish with BioMed Central    and   every 
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both alcohol dependant and non-alcohol dependent sam-
ples to consolidate this finding. Stratification of further
samples into early and late onset alcohol dependence may
also be of use.
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